A dramatic restructuring at AfroCentric Investment Corporation has seen the group swing to a significant basic loss of R1.27bn for the period ending December 2025, despite a nearly two-fold increase in turnover. The JSE-listed healthcare giant is currently navigating a complex transition period as it strips away non-core assets to lean into its primary medical administration functions. According to a report by Business Day, while total revenue from continuing operations surged by 93.9 per cent to reach R7.30bn, the bottom line was severely impacted by asset impairments totalling approximately R1.59bn.
The group, which serves as the parent company to South Africa’s largest medical scheme administrator, Medscheme, has opted to withhold a dividend payment as it manages the financial fallout from discontinued business units. As reported by Moneyweb, the loss of 151.55c per share is largely technical, stemming from the exit of the Activo Group and the disposal of the ADS and Wellworx divisions. These strategic moves are designed to simplify the corporate structure following the acquisition of a 59 per cent controlling stake in the company by Sanlam Life Insurance.
Despite the headline loss, the underlying operational performance showed signs of health with headline earnings rising to R117.1m. This growth reflects the scale of the group’s specialist medicine provider, Pharmacy Direct, and its dominant position in the managed care market. According to analysis from Reuters, the sale of the broker support and financial services arms to Sanlam represents a pivot away from auxiliary services toward a consolidated healthcare delivery model. This shift in strategy occurs as the broader South African healthcare sector faces increased scrutiny over costs and the long-term implementation of national health initiatives.